Lillys Oral GLP-1 Drug Orforglipron Succeeds in Phase 3 Trial, Poised to Reshape Diabetes/Obesity Treatment Landscape Release Time: 2025-04-21 News Source: Lilly Author: SENOVALucas Recently, Eli Lilly announced that its oral GLP-1 receptor agonist Orforglipron achieved positive results in a Phase 3 clinical trial for patients with type 2 diabetes and obesity, meeting primary efficacy endpoints with a safety profile consistent with existing injectable GLP-1 drugs
How does rapid weight loss from GLP-1 drugs compare to surgical weight loss procedures
Medications included semaglutide (AOM and ADM, oral and injectable), liraglutide (AOM and ADM), exenatide (ADM), lixisenatide (ADM), tirzepatide (AOM and ADM), and dulaglutide (ADM)
Med Supply Solutions
Benefits of Glutathione for Face Glow Brightens complexion naturally Reduces hyperpigmentation & melasma Fights signs of aging (wrinkles, fine lines, dullness) Improves skin elasticity & texture Protects skin from UV damage & environmental stress Detoxifies for clearer skin Boosts overall radiance and glow Steris Skincare Solutions with Glutathione At Steris Healthcare Pvt
